Business
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p £ 0.016). \n\n \n \n \n \n \n \n\n \nStudy design and results:\nBoth the experimental and the control groups were inoculated with human colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham control were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Previously published interim results showing a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p value £ 0.022. The study was concluded after 16 days of treatment (day 21) when a member of the control group reached a predetermined tumor size. Final results recorded a significant and robust 33% reduction in tumor volume in RCC-33 treated mice in comparison with the control group, p value £0.016.\nEyal Barad, Cannabics Pharmaceuticals' Co-founder and CEO said: \"The outlook of the oncology market puts this sector's therapeutics sales forecast at $250 billion by 2024, according to a recent McKinsey report. While t...